Clinical trials: Stage IIIB Non Small Cell Lung Cancer
Advanced Stage Non Small Cell Lung Cancer
Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc
This study is a multicenter, randomized, open-label Phase II trial that compares reduced dose erlotinib 100mg daily and standard dose gefitinib 250mg daily in patients with advanced non-small cell lung cancer who harbor EGFR…
- Trial name
- NSCLC EGFR TKI (NCT01955421)
- Testing
- Erlotinib 100mg qd, Gefitinib 250mg qd
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer
A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
This clinical study will help determine if giving OGX-011 (custirsen sodium) in combination with gemcitabine (GEM) and cisplatin (CIS) or carboplatin (CARB) is a safe and effective treatment for patients with lung cancer.
- Trial name
- NCT00138658
- Testing
- custirsen sodium
- Where
- 15 sites in United States, Canada
- Volunteers
- 85 people
- Sponsor
- Achieve Life Sciences
NSCLC
Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
This study is a prospective, multicenter, real-world study to investigate the efficacy and safety of bevacizumab plus epidermal growth factor (EGFR) Tyrosine Kinase Inhibitors in Chinese Patients With Stage IIIB/IV EGFR-mutant…
- Trial name
- BELLA (NCT04575415)
- Testing
- Bevacizumab, Erlotinib, Gefitinib
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-small Cell Lung Cancer Stage IIIB/IV
Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor
Oral chemotherapeutic drugs were analyzed in patients with driver gene negative locally advanced/advanced non-small cell lung cancer with PS score 2 A prospective, single-arm, multicenter, observational study on the efficacy and…
- Trial name
- NCT06310915
- Testing
- Navelbine oral,Pembrolizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
NSCLC, EGFR Positive Non-small Cell Lung Cancer
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
An Open-label, Single-arm, Phase II Clinical Study of Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma.
- Conditions
- NSCLC, EGFR Positive Non-small Cell Lung Cancer, Neoadjuvant Therapy
- Trial name
- NCT07622706
- Testing
- Firmonertinib 80mg qd oral for 8 weeks., Firmonertinib 160mg qd oral for 8 weeks., Firmonertinib 80mg qd oral for 16 weeks.
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Lung Cancer
Serum and Exhaled Breath Condensate MALDI-MS of Lung Cancer. (SPORE)
RATIONALE: Collecting and storing samples of blood and exhaled breath from patients with cancer and from healthy participants to study in the laboratory may help doctors learn more about changes that occur in DNA and identify…
- Trial name
- NCT00898209
- Testing
- protein expression analysis, proteomic profiling, biologic sample preservation procedure
- Volunteers
- 564 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Non-Small Cell Lung Cancer
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
This open-label, randomized, parallel arm study assessed the efficacy and safety of Tarceva (erlotinib) versus gemcitabine/cisplatin combination chemotherapy as first-line treatment in patients with stage IIIB/IV non-small cell…
- Trial name
- NCT01342965
- Testing
- Erlotinib, Chemotherapy
- Where
- 28 sites in China, Malaysia and 1 more
- Volunteers
- 217 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
The primary purpose of this study is to look at effects, good or bad, of combining two investigational anti-cancer drugs called MPDL3280A and CDX-1401.
- Trial name
- NCT02495636
- Testing
- CDX-1401, MPDL3280A
- Where
- United States
- Sponsor
- Yale University
Lung Cancer
4D Image-guided Adaptive Radiotherapy for Lung Cancer: Patient Image Acquisition
This clinical trial studies 4-dimensional (4-D) image-guided radiation therapy treatment planning in patients with stage I-IV non-small cell lung cancer.
- Trial name
- NCT01018147
- Testing
- 4-dimensional computed tomography
- Volunteers
- 22 people
- Sponsor
- Virginia Commonwealth University
Non-Small Cell Lung Cancer
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
This is a clinical trial to determine the safety and tolerability of MK0683 in combination with gemcitabine and cisplatin and/or carboplatin.
- Trial name
- NCT00423449
- Testing
- vorinostat, Gemcitabine, Platinum-based agent
- Volunteers
- 61 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma With High Risk of Brain Metastasis
Lung cancer is the first cause of death among cancer patients. Non Small Cell lung cancer (NSCLS) represents about 80-85% of the cases. Of this, about 80% presents with locally advanced or metastatic disease.
- Trial name
- PCI (NCT01603849)
- Testing
- Prophylactic Cranial Irradiation
- Where
- Mexico
- Volunteers
- 84 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial
Clinical Trial Protocol Primary Objective: To evaluate the efficacy of the Xingbaiji Formula combined with chemotherapy and Sintilimab as first-line therapy in patients with recurrent or metastatic Stage IIIB-IV EGFR/ALK/ROS-1…
- Conditions
- Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
- Trial name
- NCT06848426
- Testing
- Xingbaiji Formula
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jiangxi Provincial People's Hopital
NSCLC Stage IIIB~IV
A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
MS-20 was approved as the first oral cancer adjuvant new drug indicated for ameliorating fatigue and appetite loss associated with cancer chemotherapy via reshaping human gut ecosystem and restoring immunity.
- Trial name
- NCT04909034
- Testing
- MS-20
- Where
- 7 sites in Taiwan
- Volunteers
- 15 people
- Sponsor
- Microbio Co Ltd
Lung Cancer
HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598
RATIONALE: Collecting samples of tumor tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00896909
- Testing
- gene expression analysis, mutation analysis, polymerase chain reaction
- Volunteers
- 44 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lung Cancer
Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC
RATIONALE: Drugs used in chemotherapy, such as vinflunine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00519831
- Testing
- cetuximab, vinflunine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-Small-Cell Lung Carcinoma
Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.
This study wants to assess different intensive therapy sequences for the treatment of non-small-cell lung cancer. It claims less on the efficacy of different chemotherapy combinations, than more on the comparison of different…
- Trial name
- NCT00148395
- Testing
- Gemcitabine, Navelbine, Carboplatin
- Where
- Germany
- Volunteers
- 280 people
- Sponsor
- Aktion Bronchialkarzinom e.V.
Lung Cancer
Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00560495
- Testing
- ammonium tetrathiomolybdate, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Non-small Cell Lung Cancer
Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) such as erlotinib have proved effective in second or third line therapy for advanced non-small cell lung cancer(NSCLC).It is well tolerated without the side…
- Trial name
- ML20981 (NCT00874419)
- Testing
- erlotinib, gemcitabine/carboplatin
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Tongji University
Lung Cancer
Palliative Care Teaching Sessions for Family Caregivers of Patients With Non-Small Cell Lung Cancer
RATIONALE: Palliative care teaching sessions may be more effective than standard care in improving caregiver burden, caregiver skills preparedness, quality of life, and distress in family caregivers of patients with non-small…
- Trial name
- NCT00827333
- Testing
- educational intervention, questionnaire administration, end-of-life treatment/management
- Where
- United States
- Volunteers
- 372 people
- Sponsor
- City of Hope Medical Center
Non Small Cell Lung Cancer
Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer
Single center, single arm, Phase II study designed to evaluate the feasibility of hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with 4D PET/CT-based radiation treatment planning and concurrent carboplatin and…
- Trial name
- NCT03699033
- Testing
- 2.5 Gy/fraction, Carboplatin, Paclitaxel
- Where
- United States
- Sponsor
- Stephanie Smiddy
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.